The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 10, 2017

Filed:

Sep. 07, 2007
Applicants:

Hani N. Sabbah, Waterford, MI (US);

Randall J. Lee, Hillsborough, CA (US);

Andrew G. Hinson, Washington, DC (US);

Inventors:

Hani N. Sabbah, Waterford, MI (US);

Randall J. Lee, Hillsborough, CA (US);

Andrew G. Hinson, Washington, DC (US);

Assignees:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US);

CARDIOPOLYMERS, INC., Laguna Hills, CA (US);

HENRY FORD HEALTH SYSTEM, Detroit, MI (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61M 37/00 (2006.01); A61F 2/24 (2006.01); A61L 27/38 (2006.01); A61K 9/00 (2006.01); A61L 27/20 (2006.01); A61L 27/52 (2006.01); A61M 5/14 (2006.01); A61M 5/178 (2006.01);
U.S. Cl.
CPC ...
A61F 2/2451 (2013.01); A61F 2/2481 (2013.01); A61K 9/0024 (2013.01); A61L 27/20 (2013.01); A61L 27/3873 (2013.01); A61L 27/52 (2013.01); A61M 5/14 (2013.01); A61M 5/178 (2013.01); A61M 37/00 (2013.01); A61M 37/0069 (2013.01); A61F 2002/249 (2013.01); A61F 2250/0067 (2013.01); A61L 2400/06 (2013.01);
Abstract

Cardiomyopathy may be treated by distributing space-occupying agent within the myocardium in a pattern about one or more chambers of the heart, such that the space-modifying agent integrates into and thickens at least part of the cardiac wall about the chamber so as globally to reduce wall stress and stabilize or even reduce chamber size. Some patterns also cause a beneficial global reshaping of the chamber. These changes occur quickly and are sustainable, and have a rapid and sustainable therapeutic effect on cardiac function. Over time the relief of wall stress reduces oxygen consumption and promotes healing. Moreover, various long-term therapeutic effects may be realized depending on the properties of the space-occupying agent, including combinations with other therapeutic materials. Specific cardiac conditions treatable by these systems and methods include, for example, dilated cardiomyopathy (with or without overt aneurismal formations), congestive heart failure, and ventricular arrhythmias. Patterns of distribution of space-occupying agent within the myocardium for global resizing may also be used or augmented to treat localized conditions such as myocardial infarctions, overt aneurysm of the ventricular wall as typically forms in response to large transmural myocardial infarctions, and mitral regurgitation due to a noncompliant mitral valve. These techniques may also be used to treat localized conditions that may not yet have progressed to cardiomyopathy.


Find Patent Forward Citations

Loading…